Table 2.
Effect of Intravenous Administration of MAA on EAAU
| MAA i.v. (μg) | OVA i.v. (μg) | PBS i.v. (μl) | Eyes with EAAU
|
Day of onset | Duration of disease (days) | ||
|---|---|---|---|---|---|---|---|
| Incidence | Mild | Severe | |||||
| 100 | 0 | 400 | 8/8 | 0/8 | 8/8 | 14 ± 1 | 12 ± 1 |
| 200 | 0 | 400 | 7/8 | 5/8 | 2/8 | 15 ± 1 | 10 ± 1 |
| 400 | 0 | 400 | 0/24 | ||||
| 0 | 400 | 400 | 24/24 | 0/24 | 24/24 | 14 ± 1 | 12 ± 1 |
| 0 | 0 | 400 | 24/24 | 0/24 | 24/24 | 14 ± 1 | 12 ± 0.5 |
EAAU, Experimental autoimmune anterior uveitis; MAA, melanin-associated antigen; OVA, ovalbumin; PBS, phosphate buffered saline; i.v., intravenous.
Incidence of EAAU given as positive/total eyes after clinical examination. Severity of inflammation on histopathological examination was grouped as normal (0), mild (1+ to 2+), or severe (3+ to 4+).